Changes in US lifetime heroin use and heroin use disorder prevalence from the 2001-2002 to 2012-2013 national epidemiologic survey on alcohol and related conditions

JAMA Psychiatry

Volumn 74, Issue 5, 2017, Pages 445-455

  Martins, Silvia S ^a   Sarvet, Aaron ^a   Santaella Tenorio, Julian ^a   Saha, Tulshi ^b   Grant, Bridget F ^b   Hasin, Deborah S ^a,c  

^a Columbia University ^*  (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; OPIATE; PSYCHEDELIC AGENT; SEDATIVE AGENT; TRANQUILIZER;

ADULT; AGE; DISEASE CLASSIFICATION; DRUG USE; DSM-IV; EDUCATIONAL STATUS; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL DISEASE ASSESSMENT; NATIONAL HEALTH ORGANIZATION; POVERTY; PRESCRIPTION; PREVALENCE; RACE; REVIEW; SOCIAL PROBLEM; STRUCTURED INTERVIEW; SUBSTANCE USE; ADOLESCENT; CAUCASIAN; DRUG MISUSE; ETHNOLOGY; HEALTH SURVEY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SURVEYS; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; PRESCRIPTION DRUG MISUSE; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 85018753220     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.0113     Document Type: Review

References (75)

1. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154-163.
2. Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18through 64years in the United States, 2003-2013. JAMA. 2015;314(14): 1468-1478.
3. Darke S, Marel C, Mills KL, Ross J, Slade T, Tessson M. Years of potential life lost amongst heroin users in the Australian Treatment Outcome Study cohort, 2001-2015. Drug Alcohol Depend. 2016;162:206-210.
4. Lopez-Quintero C, Roth KB, Eaton WW, et al. Mortality among heroin users and users of other internationally regulated drugs: a 27-year follow-up of users in the Epidemiologic Catchment Area Program household samples. Drug Alcohol Depend. 2015;156:104-111.
5. Martins SS, Sampson L, Cerdá M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health. 2015;105(11):e29-e49.
6. Centers for Disease Control and Prevention. Today's Heroin Epidemic: More People at Risk, Multiple Drugs Abused. https://www.cdc.gov/vitalsigns/heroin/index.html. Updated July 7, 2015. Accessed June 15, 2016.
7. Rondinelli AJ, Ouellet LJ, Strathdee SA, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104(1-2):167-174.
8. Yen CN, Wang CS, Wang TY, Chen HF, Chang HC. Quality of life and its correlates among heroin users in Taiwan. Kaohsiung J Med Sci. 2011;27(5):177-183.
9. Csete J, Kamarulzaman A, Kazatchkine M, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427-1480.
10. Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network Methodology Report, 2011 Update. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
11. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
12. Muhuri PK, Gfroerer JC, Davies C. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use inthe United States. CBHSQ Data Review. http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf. Published August 2013. Accessed October 16, 2016.
13. Cicero TJ, Kuehn BM. Driven by prescription drug abuse, heroin use increases among suburban and rural whites. JAMA. 2014;312(2):118-119.
14. Cicero TJ, Ellis MS. Nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(13):1295-1296.
15. Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015;373(18):1789-1790.
16. Ihongbe TO, Masho SW. Prevalence, correlates and patterns ofheroin use among young adults in the United States. Addict Behav. 2016;63:74-81.
17. Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users-United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719-725.
18. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015; 72(8):757-766.
19. Grant BF, Stinson FS, Dawson DA, Chou SP, Ruan WJ, Pickering RP. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61 (4):361-368.
20. Grant BF, Moore TC, Kaplan K. Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2003.
21. Grant BF, Amsbary M, Chu A, et al. Source and Accuracy Statement: National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 2014.
22. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
23. Substance Abuse and Mental Health Services Administration. Results From the 2012 National Surveyon Drug Use and Health: Summary of National Findings, Appendix B: Statistical Methods and Measurement. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
24. Adams PF, Kirzinger WK, Martinez ME; National Center for Health Statistics. Summary health statistics for US adults: National Health Interview Survey, 2012. Vital Health Stat 2013;10(259).
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
27. Canino G, Bravo M, Ramírez R, et al. The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population. J Stud Alcohol. 1999;60(6):790-799.
28. Chatterji S, Saunders JB, Vrasti R, Grant BF, Hasin D, Mager D. Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule-Alcohol/Drug-Revised (AUDADIS-ADR): an international comparison. Drug Alcohol Depend. 1997;47(3):171-185.
29. Cottler LB, Grant BF, Blaine J, et al. Concordance of DSM-IV alcohol and drug use disorder criteria and diagnoses as measured by AUDADIS-ADR, CIDI and SCAN. Drug Alcohol Depend. 1997;47(3):195-205.
30. Grant BF. DSM-IV, DSM-III-R, and ICD-10 alcohol and drug abuse/harmful use and dependence, United States, 1992: a nosological comparison. Alcohol Clin Exp Res. 1996;20(8):1481-1488.
31. Grant BF, Dawson DA, Stinson FS, Chou PS, Kay W, Pickering R. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend. 2003;71 (1):7-16.
32. Grant BF, Harford TC, Dawson DA, Chou PS, Pickering RP. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend. 1995;39(1):37-44.
33. Nelson CB, Rehm J, Ustün TB, Grant B, Chatterji S. Factor structures for DSM-IV substance disorder criteria endorsed by alcohol, cannabis, cocaine and opiate users: results from the WHO reliability and validity study. Addiction. 1999;94(6):843-855.
34. Pull CB, Saunders JB, Mavreas V, et al. Concordance between ICD-10 alcohol and drug use disorder criteria and diagnoses as measured by the AUDADIS-ADR, CIDI and SCAN: results ofa cross-national study. Drug Alcohol Depend. 1997;47 (3):207-216.
35. Ustün B, Compton W, Mager D, et al. WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. Drug Alcohol Depend. 1997;47(3):161-169.
36. Vrasti R, Grant BF, Chatterji S, et al. Reliability of the Romanian version of the alcohol module of the WHO Alcohol Use Disorder and Associated Disabilities: Interview Schedule-Alcohol/Drug-Revised. Eur Addict Res. 1998;4(4):144-149.
37. Grant B, Harford TC, Dawson DA, Chou PS, Dufour M, Pickering R. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. NIAAA Epidemiology Bull. 1994;18(3):243-248.
38. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1995;7(4): 481-497.
39. Grant BF, Dawson DA, Hasin DS. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2001.
40. Hasin D, Carpenter KM, McCloud S, Smith M, Grant BF. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. Drug Alcohol Depend. 1997;44(2-3):133-141.
41. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834-851.
42. Thompson RG Jr, Alonzo D, Hu MC, Hasin DS. Substance use disorders and poverty as prospective predictors of adult first-time suicide ideation or attempt in the United States [published online July 16, 2016]. Community Ment Health J. doi:10.1007/s10597-016-0045-z
43. Saha TD, Kerridge BT, Goldstein RB, et al. Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the United States. J Clin Psychiatry. 2016;77(6):772-780.
44. Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2016; 73(1):39-47.
45. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol. 2010;171(5):618-623.
46. Research Triangle Institute. SUDAAN Language Manual, Release 11.0. Research Triangle Park, NC: Research Triangle Institute; 2012.
47. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659.
48. Centers for Disease Control and Prevention. Vital Signs: Today's Heroin Epidemic-More People at Risk, Multiple Drugs Abused. https://www.cdc.gov/vitalsigns/heroin/. Updated July 7, 2015. Accessed December 28, 2016.
49. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821-826.
50. Compton WM, Jones CM, Baldwin GT. Nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(13):1296.
51. Martins SS, Santaella-Tenorio J, Marshall BD, Maldonado A, Cerdá M. Racial/ethnic differences in trends in heroin use and heroin-related risk behaviors among nonmedical prescription opioid users. Drug Alcohol Depend. 2015;151:278-283.
52. Meghani SH, Byun E, Gallagher RM. Time to take stock: a meta-analysis and systematic review of analgesic treatment disparities for pain in the United States. Pain Med. 2012;13(2):150-174.
53. Drug Enforcement Administration. National Drug Threat Assessment Summary 2014 [publication DEA-DCT-DIR-002-15]. Washington, DC: US Departmentof Justice, Drug Enforcement Administration; 2015.
54. Unick G, Rosenblum D, Mars S, Ciccarone D. The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. Addiction. 2014;109(11):1889-1898.
55. Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alcohol Depend. 2016;160:127-134.
56. Cerdá M, Santaella J, Marshall BD, Kim JH, Martins SS. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study. J Pediatr. 2015;167(3):605-12.e1-2.
57. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013;132(1-2):95-100.
58. Carliner H, Mauro PM, Brown QL, et al. The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002-2014. Drug Alcohol Depend. 2017;170(1):51-58.
59. Kerr WC, Greenfield TK, Bond J, Ye Y, Rehm J. Age-period-cohort influences on trends in past year marijuana usein theUSfrom the 1984, 1990, 1995 and 2000 National Alcohol Surveys. Drug Alcohol Depend. 2007;86(2-3):132-138.
60. National Employment Law Project. The Low-Wage Recovery: Industry Employment and Wages Four Years Into the Recovery. New York, NY: National Employment Law Project; 2014.
61. Rigg KK, Monnat SM. Comparing characteristics of prescription painkiller misusers and heroin users in the United States. Addict Behav. 2015;51:106-112.
62. Martins S, Ko J, Kuwabara S, et al. The relationship of adult mental disorders to race, socioeconomic status, marital status, and urbanicity of residence. In: Eaton W, ed. Public Mental Health. New York, NY: Oxford University Press; 2012:151-200.
63. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci USA. 2015;112(49):15078-15083.
64. Nyamathi A, Salem BE, Farabee D, et al. Correlates of heroin and methamphetamine use among homeless male ex-jail and prison offenders. Addict Res Theory. 2014;22(6):463-473.
65. Karberg J, James D. Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics; 2005.
66. Glaze LE, Kaeble D. Correctional Populations in the United States, 2013. Washington, DC: Department of Justice, Bureau of Justice Statistics; 2014.
67. Mauer M, King RA. 25-Year Quagmire: The War on Drugs and its Impact on American Society. Washington, DC: The Sentencing Project; 2007.
68. Carson EA. Prisoners in 2014. Washington, DC: Bureau of Justice Statistics; 2015.
69. Hasin DS, Greenstein E, Aivadyan C, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample. Drug Alcohol Depend. 2015;148:40-46.
70. Zhao J, Stockwell T, Macdonald S. Non-response bias in alcohol and drug population surveys. Drug Alcohol Rev. 2009;28(6):648-657.
71. Williams AR, Bisaga A. From AIDS to opioids-how to combat anepidemic. N Engl J Med. 2016;375(9):813-815.
72. Spoth R, Trudeau L, Shin C, et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. Am J Public Health. 2013;103(4):665-672.
73. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
74. Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. Clinicians' use of prescription drug monitoring programs in clinical practice and decision-making [published online October 29, 2016]. Pain Med. pii:pnw251.
75. Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35(7):1324-1332.